Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
2901
-
2902
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2903
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2904
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2905
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2906
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2907
-
2908
-
2909
-
2910
General characteristics of study subjects.
Published 2025“…COVID-19 did not affect inpatient mortality (p = 0.9608), but in-hospital mortality decreased from 12% to 7% in the medical aid group.</p><p>Conclusion</p><p>Overall, we found that COVID-19 had an impact on admission rates of patients with AMI but did not have a significant impact on in-hospital mortality. …”
-
2911
-
2912
Dataset visualization diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2913
Dataset sample images.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2914
Performance comparison of different models.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2915
C2f and BC2f module structure diagrams.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2916
YOLOv8n detection results diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2917
YOLOv8n-BWG model structure diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2918
BiFormer structure diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2919
YOLOv8n-BWG detection results diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
-
2920
GSConv module structure diagram.
Published 2025“…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”